DE69723429T3 - Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS - Google Patents

Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS Download PDF

Info

Publication number
DE69723429T3
DE69723429T3 DE69723429T DE69723429T DE69723429T3 DE 69723429 T3 DE69723429 T3 DE 69723429T3 DE 69723429 T DE69723429 T DE 69723429T DE 69723429 T DE69723429 T DE 69723429T DE 69723429 T3 DE69723429 T3 DE 69723429T3
Authority
DE
Germany
Prior art keywords
bmp
res
xaa
morphogen
gdf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69723429T
Other languages
German (de)
English (en)
Other versions
DE69723429D1 (de
DE69723429T2 (de
Inventor
F. Marc CHARETTE
P. Seth FINKLESTEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Stryker Corp
Original Assignee
General Hospital Corp
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69723429(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Curis Inc filed Critical General Hospital Corp
Publication of DE69723429D1 publication Critical patent/DE69723429D1/de
Application granted granted Critical
Publication of DE69723429T2 publication Critical patent/DE69723429T2/de
Publication of DE69723429T3 publication Critical patent/DE69723429T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Protection Of Generators And Motors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69723429T 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS Expired - Lifetime DE69723429T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US620444 1996-03-22
PCT/US1997/004177 WO1997034626A1 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Publications (3)

Publication Number Publication Date
DE69723429D1 DE69723429D1 (de) 2003-08-14
DE69723429T2 DE69723429T2 (de) 2004-04-22
DE69723429T3 true DE69723429T3 (de) 2007-09-20

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69723429T Expired - Lifetime DE69723429T3 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
DE69740089T Expired - Lifetime DE69740089D1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69740089T Expired - Lifetime DE69740089D1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS

Country Status (11)

Country Link
US (4) US6214796B1 (enExample)
EP (3) EP0894004B2 (enExample)
JP (2) JP4847634B2 (enExample)
KR (1) KR20000064752A (enExample)
CN (1) CN1181885C (enExample)
AT (2) ATE493141T1 (enExample)
AU (2) AU725341B2 (enExample)
CA (2) CA2249368A1 (enExample)
DE (2) DE69723429T3 (enExample)
ES (1) ES2201287T5 (enExample)
WO (2) WO1997034626A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
DK0698094T3 (da) 1993-05-12 2004-05-03 Inst Genetics Llc BMP-11-sammensætninger
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
WO1998050060A1 (en) * 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
CA2291514C (en) * 1997-05-30 2011-07-12 Mariel Therapeutics, Inc. Methods for evaluating tissue morphogenesis and activity
EP1037910A2 (en) * 1997-12-04 2000-09-27 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
IL148175A0 (en) * 1999-08-18 2002-09-12 Gen Hospital Corp Methods, compositions and kits for promoting recovery from damage to the central nervous system
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
AU2001268147B2 (en) * 2000-06-01 2006-05-04 Children's Medical Center Corporation Methods and compositions for producing a neurosalutary effect in a subject
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
WO2002099037A2 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
KR20040048379A (ko) * 2001-06-01 2004-06-09 싸이트 테라피스 인코포레이티드 Ｔ 세포 유도된 조직 복구 및 재생
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
BR0316560A (pt) 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
DE60334250D1 (de) 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
CA2897218A1 (en) 2004-06-17 2006-01-26 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
WO2006012365A2 (en) * 2004-07-20 2006-02-02 University Of Maryland Protease inhibitor
EP1782821A4 (en) * 2004-07-29 2009-11-11 Anges Mg Inc MEDICAMENT AND METHOD FOR IMPROVING BRAIN FUNCTION
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
PT2497780E (pt) 2005-09-20 2015-08-20 Thrasos Innovation Inc Compostos relacionados com tdf e seus análogos
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
SI2121142T1 (sl) * 2007-01-25 2012-12-31 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Uporaba GDF-5 za izboljšanje ali vzdrževanje videza kože
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
US20100204124A1 (en) * 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
WO2010093925A2 (en) * 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
AU2010223268B2 (en) 2009-03-12 2015-04-23 Haase Investments Gmbh Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
CA2785038A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
WO2012023113A2 (en) 2010-08-20 2012-02-23 Wyeth Llc Designer osteogenic proteins
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
US20140057831A1 (en) * 2011-07-19 2014-02-27 Thrasos Innovation, Inc. Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
EP3007719B1 (en) * 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
JP2021529835A (ja) * 2018-07-03 2021-11-04 ベンチュリス セラピューティクス， インク．Ｖｅｎｔｕｒｉｓ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 脳卒中を治療するための組成物及び方法
WO2021165465A1 (en) * 2020-02-20 2021-08-26 Universiteit Maastricht Detection method of circulating bmp10 (bone morphogenetic protein 10)
US20230263860A1 (en) * 2020-05-19 2023-08-24 Elevian, Inc. Methods And Compositions For Treating Stroke
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
WO1990000619A1 (en) 1988-07-08 1990-01-25 University College London Analysis of cell modifying substances
AU4056089A (en) 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
ES2118723T3 (es) 1989-10-17 1998-10-01 Stryker Corp Dispositivos osteogenicos.
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
DE69131580T2 (de) 1990-06-15 2000-01-13 Carnegie Institution Of Washington, Washington GDF-1 und UOG1 Proteine
DE69133338T2 (de) 1990-09-26 2004-04-15 Genetics Institute, LLC, Cambridge Bmp-5-derivate
JPH07500487A (ja) 1990-10-18 1995-01-19 ストライカー コーポレイション 骨形成ペプチド
ATE194169T1 (de) 1990-11-16 2000-07-15 Celtrix Pharma Beta-type ähnlicher transformierender wachstumfaktor
EP0564502B1 (en) 1990-11-27 2002-01-30 The American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
EP0513334A4 (en) 1990-11-30 1993-08-04 Celtrix Laboratories, Inc. Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
AU660019B2 (en) * 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
AU662155B2 (en) 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
JP3351525B2 (ja) 1991-06-21 2002-11-25 ジェネティックス・インスティテュート・インコーポレイテッド 骨形成性蛋白医薬処方物
KR100255415B1 (ko) 1991-06-25 2000-05-01 브루스 엠. 에이센 비엠피-9 조성물
DE69233559T2 (de) 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
ATE197611T1 (de) 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
CA2116562C (en) 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
WO1993009802A2 (en) 1991-11-22 1993-05-27 Genentech, Inc. Tgf-beta to improve neural outcome
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
EP0653942B2 (en) * 1992-07-31 2007-03-07 Curis, Inc. Morphogen-induced nerve regeneration and repair
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
EP1716864A1 (en) † 1993-08-26 2006-11-02 Genetics Institute, LLC Neural regeneration using home bone morphogenetic proteins
WO1995006656A1 (en) 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
AU701623B2 (en) 1993-10-14 1999-02-04 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues

Also Published As

Publication number Publication date
CN1219133A (zh) 1999-06-09
CA2249596A1 (en) 1997-09-25
ATE244574T1 (de) 2003-07-15
AU2582397A (en) 1997-10-10
AU725341B2 (en) 2000-10-12
WO1997034626A1 (en) 1997-09-25
CN1181885C (zh) 2004-12-29
ES2201287T5 (es) 2007-10-16
WO1997034618A1 (en) 1997-09-25
US6214796B1 (en) 2001-04-10
CA2249368A1 (en) 1997-09-25
EP1364655B1 (en) 2010-12-29
KR20000064752A (ko) 2000-11-06
ATE493141T1 (de) 2011-01-15
DE69723429D1 (de) 2003-08-14
EP1364655A1 (en) 2003-11-26
CA2249596C (en) 2011-11-08
EP0904093A4 (en) 2004-11-17
US20010039261A1 (en) 2001-11-08
EP0894004B2 (en) 2007-02-21
EP0894004A1 (en) 1999-02-03
JP2000506894A (ja) 2000-06-06
DE69740089D1 (de) 2011-02-10
ES2201287T3 (es) 2004-03-16
DE69723429T2 (de) 2004-04-22
US6407060B1 (en) 2002-06-18
US20030022830A1 (en) 2003-01-30
AU734312B2 (en) 2001-06-07
AU2552997A (en) 1997-10-10
JP4847634B2 (ja) 2011-12-28
EP0894004B1 (en) 2003-07-09
EP0904093A1 (en) 1999-03-31
JP2000507939A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
DE69723429T2 (de) Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
DE69730966T2 (de) Morphogenische behandlung des chronischen nierenversagens
Hamilton et al. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin
DE69928563T2 (de) Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem
AU2008255016B2 (en) Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
DE69333040T3 (de) Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
DE69535264T2 (de) Verfahren zur behandlung von diabetes mittels kgf
DE60021388T2 (de) Monomeres protein der tgf-beta familie
DE69915310T2 (de) Methoden zur behandlung der salzabhängigen hypertonie
AU693489B2 (en) Method of treating neurological disorders
DE69626034T2 (de) Zusammensetzung für verbesserung der pankreasfunktion
DE69630811T2 (de) Knorpel und knochen bildendes material zur gewebsrückgewinnung
DE19525416A1 (de) Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
EP2352750B1 (en) Buffers for controlling the ph of bone morphogenetic proteins
DE69826854T2 (de) Therapien zur behandlung von akutem nierenversagen
DE69821793T2 (de) Neuronale verwendungen des bmp-11
DE69903612T2 (de) Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
DE69936638T2 (de) IGF-enthaltende injizierbare Formulierungen, enthaltend Succinat als Puffermittel
DE69727691T2 (de) Verwendung von keratinocyten-wachstumsfaktor-2
DE69531166T2 (de) Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen
DE69727491T2 (de) Verfahren zur verabreichung von wachstumsfaktoren
WO1996008562A1 (de) Biologisch aktive, von neurotrophinen abgeleitete moleküle
DE10317369A1 (de) proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: STRYKER CORP., KALAMAZOO, MICH., US

Owner name: THE GENERAL HOSPITAL CORP., BOSTON, MASS., US